Spesolimab Provides Sustained Improvement of GPP and QOL

In a secondary analysis of phase 2b spesolimab data in generalized pustular psoriasis (GPP), nearly two-thirds of patients who received 300 mg monthly doses maintained clear or nearly clear skin through 48 weeks’ follow-up, and nearly one quarter of treated patients maintained minimal GPP impact on quality of life (QOL…